P701 Prevalence of positive anti-tissue transglutaminase antibodies in inflammatory bowel disease patients
F. Casellas*1, 2, C. Herrera de Guise1, V. Robles1, N. Borruel1
1Hospital Universitari Vall d’Hebron, Unitat Atenció Crohn-Colitis, Barcelona, Spain, 2Hospital Universitari Vall d’Hebron, Barcelona, Spain
Inflammatory bowel disease (IBD) and celiac disease share many things in common: a similar pathophysiology, genetic locus, associated autoimmune diseases. and an increasing incidence. There are some studies and case series that have suggested an association between celiac disease and inflammatory bowel disease; however, there is considerable controversy regarding this association. Aim: to assess the presence of anti-tissue transglutaminase antibody in IBD patients.
We conducted an observational, prospective, cross-sectional study in patients with a clinical, endoscopic, and histologic IBD diagnosis. IgA tissue transglutaminase antibodies (anti-tTG) was determined in all included patients, unless there was an IgA deficiency detected, and then IgG anti-tTG was determined. If antibody levels were positive, an endoscopic duodenal biopsy was indicated. Celiac disease was diagnosed in all patients with positive anti-tTG, a compatible duodenal biopsy, and good response to a gluten-free diet. We compared the prevalence of celiac disease in our group with the expected prevalence in the general population according to published adult series of national studies.
We included 407 IBD patients in our study. There were 224 female patients and 58% had Crohn’s disease, and median age was 37 years. We found 5 patients (1.2%) with celiac disease, and in 2, celiac disease diagnosis preceded IBD diagnosis. No differences between type of IBD, gender, disease duration, age, presence of extraintestinal manifestations, or extension or behaviour of disease were found. The expected prevalence of celiac disease in the general population of our region in the same age group is 0.47%, the prevalence in our group was not different (exact Fishers’ test, p = 0.2).
Screening in inflammatory bowel disease patients with anti-tTG enables detection of patients with celiac disease. The prevalence of celiac disease in IBD is similar to that in the general population.